EIC Accelerator Winner Ganymed Robotics in the Knee Robot Race

Knee replacement is, as Ganymed's 2021 EIC announcement put it, a common and fast-growing operation, and most joint replacements are still done without technological help. Many existing surgical robots track the anatomy with optical markers fixed to pins in the patient's bones. Ganymed Robotics, founded in Paris in 2018, is building a robotic assistant that tracks the knee with cameras and computer vision instead, with no markers at all.

The European Innovation Council granted €2,485,995.75 towards a two-year, €3.55 million project to finish the robot. Investors have since put €36 million into the company. As of early 2026 the system was still under development and not approved for clinical use. Separately, the co-founder who led the company left in 2025.

Where Ganymed Stands Today

Ganymed is still a development-stage medtech. A February 2026 profile described its system as under development, with preclinical testing but no peer-reviewed clinical results and no approval for commercial use. In 2025 the company changed leadership: co-founder Sophie Cahen, who had led it since the start, left; Michel Thérin became executive chairman and Frédéric Banegas interim chief executive and chief operating officer. The French register on Pappers records the change of president in mid-2025.

The company is well capitalised for its stage. Its Series B raised €21 million in 2022 and a €15 million extension in 2023, according to Crédit Mutuel Innovation and The Robot Report, and the EIC Fund lists it in its portfolio.

The Technology: Seeing the Knee Without Markers

An orthopaedic robot needs to know exactly where the bones are. Marker-based systems achieve this with arrays fixed to pins in the femur and tibia, which Ganymed's marker-less approach is designed to avoid. Ganymed's approach, set out in its CORDIS objective, is "contactless anatomical localization" with computer vision: cameras and algorithms recognise and track the bone surfaces directly. The robot is co-manipulated, meaning the surgeon guides it while it constrains the cuts to the plan.

The company's pitch is also economic: a "compact, ergonomic, intuitive, and cost-effective" device aimed at the 95% of procedures that, according to the objective, still use no technological assistance, in part because current robots are large and expensive.

What the EIC Project Promised, and What CORDIS Shows

The project ran from 1 January 2022 to 31 December 2023. Its report is detailed. The hardware design was finalised and the robot entered verification and validation. Software development and industrialisation followed the proof of concept. A non-interventional clinical study called Valalgon enrolled 91 patients to validate the vision algorithms on real anatomy, and twelve cadaver labs had been run by the end of 2023, including full prosthesis implantation with commercial implants. The R&D team grew from 23 to 41 full-time equivalents.

1. A finished robot designDeliveredHardware finalised and in verification and validation by the end of 2023.
2. Marker-less navigation provenPartialProof of concept on patient data (91 patients, observational) and cadavers; no peer-reviewed results.
3. Regulatory clearanceNot yetNo submission reported on CORDIS; not approved as of February 2026.
4. Use in surgeryNone publishedNo first-in-human operation announced.

What Has Happened Since the Award

The Money

The accounts on Pappers show a company spending at the pace of a medical device heading for approval: net losses of €413,000 in 2021, €1.03 million in 2022, €5.53 million in 2023 and €5.03 million in 2024. Equity rose from €1.33 million to €29.9 million with the Series B and stood at €27.6 million at the end of 2024. The register lists no insolvency proceedings.

Why Europe Should Care

A European surgical robotics company with a distinct technical approach, funded by French investors, the EIC grant and the EIC Fund, keeps development of this technology in Europe. The CORDIS objective also points to an ageing population driving demand for joint replacement, a pressure felt across European health systems.

The Verdict

Ganymed Robotics has not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.